Mitochondrial transfer in hematological malignancies

被引:9
|
作者
Guo, Xiaodong [1 ]
Can, Can [1 ]
Liu, Wancheng [1 ]
Wei, Yihong [1 ]
Yang, Xinyu [1 ]
Liu, Jinting [1 ]
Jia, Hexiao [1 ]
Jia, Wenbo [1 ]
Wu, Hanyang [1 ]
Ma, Daoxin [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Hematol, Jinan 250012, Shandong, Peoples R China
关键词
Mitochondrial transfer; Tunneling nanotubes; Extracellular vesicles; Extracellular mitochondria; Hematological malignancies; MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; CHRONIC MYELOGENOUS LEUKEMIA; TUNNELING NANOTUBES; EXTRACELLULAR VESICLES; INTERCELLULAR COMMUNICATION; MULTIPLE-MYELOMA; TNT FORMATION; CANCER-CELLS; IN-VITRO;
D O I
10.1186/s40364-023-00529-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mitochondria are energy-generated organelles and take an important part in biological metabolism. Mitochondria could be transferred between cells, which serves as a new intercellular communication. Mitochondrial transfer improves mitochondrial defects, restores the biological functions of recipient cells, and maintains the high metabolic requirements of tumor cells as well as drug resistance. In recent years, it has been reported mitochondrial transfer between cells of bone marrow microenvironment and hematological malignant cells play a critical role in the disease progression and resistance during chemotherapy. In this review, we discuss the patterns and mechanisms on mitochondrial transfer and their engagement in different pathophysiological contexts and outline the latest knowledge on intercellular transport of mitochondria in hematological malignancies. Besides, we briefly outline the drug resistance mechanisms caused by mitochondrial transfer in cells during chemotherapy. Our review demonstrates a theoretical basis for mitochondrial transfer as a prospective therapeutic target to increase the treatment efficiency in hematological malignancies and improve the prognosis of patients.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Role of Fyn in hematological malignancies
    Li, Shan
    Liu, Changqing
    Tang, Yunlian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 6759 - 6767
  • [32] The roles of TPL in hematological malignancies
    Xu, Tingyun
    Zhu, Yiwei
    Ge, Shuaishuai
    Liu, Song-Bai
    HEMATOLOGY, 2023, 28 (01)
  • [33] ANTISENSE THERAPEUTICS IN HEMATOLOGICAL MALIGNANCIES
    KIRKLAND, MA
    OBRIEN, SG
    GOLDMAN, JM
    BRITISH JOURNAL OF HAEMATOLOGY, 1994, 87 (03) : 447 - 452
  • [34] Epigenetics of hematopoiesis and hematological malignancies
    Hu, Deqing
    Shilatifard, Ali
    GENES & DEVELOPMENT, 2016, 30 (18) : 2021 - 2041
  • [35] Bacteremia in patients with hematological malignancies
    Wang, FD
    Lin, ML
    Liu, CY
    CHEMOTHERAPY, 2005, 51 (2-3) : 147 - 153
  • [36] THE THERAPY OF HEMATOLOGICAL MALIGNANCIES IN THE ELDERLY
    RESEGOTTI, L
    HAEMATOLOGICA, 1993, 78 (03) : 141 - 144
  • [37] Role of Fyn in hematological malignancies
    Shan Li
    Changqing Liu
    Yunlian Tang
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 6759 - 6767
  • [38] Gene therapy for hematological malignancies
    Schmidt-Wolf, GD
    Schmidt-Wolf, IGH
    CLINICAL AND EXPERIMENTAL MEDICINE, 2003, 3 (01) : 4 - 14
  • [39] Semaphorins and Their Receptors in Hematological Malignancies
    Wei, Li
    Li, Hongbo
    Tamagnone, Luca
    You, Hua
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [40] Antisense strategy in hematological malignancies
    Warzocha, K
    CYTOKINES CELLULAR & MOLECULAR THERAPY, 1999, 5 (01) : 15 - 23